Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals Total Payout Ratio Chart
NAVBQ vs PKBO, RSPI, ATRX: Total Payout Ratio Comparison
For the Biotechnology subindustry, Navidea Biopharmaceuticals's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navidea Biopharmaceuticals Total Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Navidea Biopharmaceuticals's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals (NAVBQ) has a Total Payout Ratio of 0.00 as of Aug. 05, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Navidea Biopharmaceuticals and its competitors.
Is Navidea Biopharmaceuticals' Total Payout Ratio too high?
Navidea Biopharmaceuticals' current Total Payout Ratio is 0.00. Overall, Navidea Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Navidea Biopharmaceuticals' Total Payout Ratio compare to PKBO and RSPI?
Navidea Biopharmaceuticals' Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Navidea Biopharmaceuticals and its competitors. Navidea Biopharmaceuticals's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navidea Biopharmaceuticals stock overvalued right now?
Navidea Biopharmaceuticals (NAVBQ) has a current Total Payout Ratio of 0.00. The current Total Payout Ratio is 0.00. Navidea Biopharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Navidea Biopharmaceuticals (NAVBQ), the current Total Payout Ratio is 0.00 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score
Get the complete analysis for NAVBQ
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAVBQ has been successfully added to your 
